Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 1
1996 3
1997 1
1998 1
1999 1
2013 2
2014 1
2020 1
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Divergence Between Clinical Trial Evidence and Actual Practice in Use of Dual Antiplatelet Therapy After Transient Ischemic Attack and Minor Stroke.
De Matteis E, De Santis F, Ornello R, Censori B, Puglisi V, Vinciguerra L, Giossi A, Di Viesti P, Inchingolo V, Fratta GM, Diomedi M, Bagnato MR, Cenciarelli S, Bedetti C, Padiglioni C, Tassinari T, Saia V, Russo A, Petruzzellis M, Mezzapesa DM, Caccamo M, Rinaldi G, Bavaro A, Paciaroni M, Mosconi MG, Foschi M, Querzani P, Muscia F, Gallo Cassarino S, Candelaresi P, De Mase A, Guarino M, Cupini LM, Sanzaro E, Zini A, La Spada S, Palmieri C, Sepe FN, Beretta S, Paci C, Caggia EA, De Angelis MV, Bonanni L, Volpi G, Tassi R, Pistoia F, Scoditti U, Tonon A, Viticchi G, Ruzza G, Nencini P, Cavallini A, Toni D, Ricci S, Sacco S; READAPT Study Group. De Matteis E, et al. Stroke. 2023 May;54(5):1172-1181. doi: 10.1161/STROKEAHA.122.041660. Epub 2023 Mar 23. Stroke. 2023. PMID: 36951052 Clinical Trial.
The THRombolysis and STatins (THRaST) study.
Cappellari M, Bovi P, Moretto G, Zini A, Nencini P, Sessa M, Furlan M, Pezzini A, Orlandi G, Paciaroni M, Tassinari T, Procaccianti G, Di Lazzaro V, Bettoni L, Gandolfo C, Silvestrelli G, Rasura M, Martini G, Melis M, Calloni MV, Chiodo-Grandi F, Beretta S, Guarino M, Altavista MC, Marcheselli S, Galletti G, Adobbati L, Del Sette M, Mancini A, Orrico D, Monaco S, Cavallini A, Sciolla R, Federico F, Scoditti U, Brusaferri F, Grassa C, Specchio L, Bongioanni MR, Sparaco M, Zampolini M, Greco G, Colombo R, Passarella B, Adami A, Consoli D, Toni D. Cappellari M, et al. Among authors: bongioanni mr. Neurology. 2013 Feb 12;80(7):655-61. doi: 10.1212/WNL.0b013e318281cc83. Epub 2013 Jan 23. Neurology. 2013. PMID: 23345634 Free PMC article.
Autoimmune events during interferon beta-1b treatment for multiple sclerosis.
Durelli L, Ferrero B, Oggero A, Verdun E, Bongioanni MR, Gentile E, Isoardo GL, Ricci A, Rota E, Bergamasco B, Durazzo M, Saracco G, Biava MA, Brossa PC, Giorda L, Pagni R, Aimo G. Durelli L, et al. Among authors: bongioanni mr. J Neurol Sci. 1999 Jan 1;162(1):74-83. doi: 10.1016/s0022-510x(98)00299-8. J Neurol Sci. 1999. PMID: 10064173 Clinical Trial.
Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis.
Durelli L, Bongioanni MR, Cavallo R, Ferrero B, Ferri R, Ferrio MF, Bradac GB, Riva A, Vai S, Geuna M, et al. Durelli L, et al. Among authors: bongioanni mr. Neurology. 1994 Mar;44(3 Pt 1):406-13. doi: 10.1212/wnl.44.3_part_1.406. Neurology. 1994. PMID: 8145906 Clinical Trial.
13 results